Ken Griffin Aligos Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,800 shares of ALGS stock, worth $1,786. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,800Holding current value
$1,786% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding ALGS
# of Institutions
53Shares Held
46.2MCall Options Held
6.11MPut Options Held
200-
Armistice Capital, LLC New York, NY6.89MShares$3.24 Million0.09% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$3 Million0.18% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$2.87 Million0.2% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$1.67 Million0.46% of portfolio
-
Altitude Crest Partners Inc. Stamford, CT2.84MShares$1.34 Million1.19% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $18.7M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...